IBGC

IGC Pharma is a clinical-stage biotechnology company focused on developing innovative therapies for Alzheimer's disease and other neurodegenerative conditions. The company leverages artificial intelligence and a deep understanding of cannabinoid medicine to advance its lead candidate, IGC-AD1, which is currently in Phase 2 clinical trials for the treatment of agitation associated with Alzheimer's dementia. IGC Pharma's approach combines traditional drug development with advanced data analytics to identify and validate novel therapeutic targets. Beyond neurology, the company explores applications for its technology in metabolic disorders and chronic pain management. IGC Pharma is committed to improving patient outcomes through scientific rigor and technological integration.